Chinese Biotech Innovation: Dominating the 2026 ADC and Bispecific Pipeline
By early 2026, Chinese biotech innovation has moved from a “fast-follower” role to a primary global engine for first-in-class oncology assets. Chinese firms now drive 70% of the global ADC…